A grim situation has emerged in Maharashtra as crore of people have been pushed to worry about employment as Covaxin from Bharat Biotech, India’s original Covid-19 vaccine, awaits WHO approval for an emergency use list.
In India’s financial capital, Covaxin was handled at more than Rs crore. Among these vaccine recipients, many of them are the sole breadwinners waiting to travel abroad to resume their work which has suffered a setback due to the delay in the WHO nod, Indian Express mentioned.
Read also | WHO official at Covaxin Nod: We trust the Indian industry, Bharat Biotech has provided data regularly
Young Dinesh Patel, who works as a waiter in a bar on a cruise ship, is considering selling his family’s gold jewelry if the bleak situation continues. “Being the sole breadwinner, I live on my hard-earned money. If this situation continues, I may have to sell my family’s gold jewelry” in another meaning.
The Report He further quoted Pushkar Nirantar, another seafarer, who was worried about losing his job as he was unable to return to his duties. “My shipping company rejected the joining letter twice due to travel restrictions,” he told the newspaper, adding that he is currently working in a “local restaurant as a chef in Badlapur”.
Hyderabad-based Bharat Biotech, which developed Covaxin, submitted an EOI (Expression of Interest) to the World Health Organization on April 19 for the Vaccine Emergency Use List (EUL).
A senior official at the World Health Agency said Thursday that the United Nations body “trusts” the Indian industry that makes high-quality vaccines.
A technical advisory group from the United Nations health agency that met on Tuesday requested “additional clarifications” from Bharat Biotech for Covaxin to make a final risk-benefit assessment of the vaccine’s emergency use list.
“Let me say Bharat has been providing data regularly and very quickly, but they sent the last batch of data on October 18th,” said Dr. Mariangela Simao, Assistant Director-General, Access to Medicines and Health Products at WHO. Geneva.. was responding to a question about the delay in granting the emergency use list for Covaxin while Chinese vaccines Sinopharm and Sinovac were given approval even with a lack of data. Simao said that when the technical advisory group met on October 26 to discuss the end-user license agreement for Covaxin, they asked Bharat Biotech Additional Clarifications The Technical Advisory Group will reconvene on 2 November for the final evaluation of the risks and benefits of Covaxin EUL.